Enterprise Value
505.7B
Cash
2.941B
Avg Qtr Burn
N/A
Short % of Float
0.70%
Insider Ownership
0.15%
Institutional Own.
83.99%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Jardiance® (empagliflozin) (anti-SGLT2) Details Diabetes, Type 2 diabetes, Chronic kidney disease | Approved Quarterly sales | |
Jaypirca (pirtobrutinib) Details Blood cancer, Cancer, Lymphoma, Mantle cell lymphoma | Approved Quarterly sales | |
Donanemab Details Alzheimer's disease | BLA Acceptance for review | |
Mirikizumab Details Ulcerative colitis | BLA Resubmission | |
Retevmo Details Medullary Thyroid Cancer | Phase 3 Data readout | |
Retevmo +/- pembrolizumab Details Non-small cell lung carcinoma | Phase 3 Data readout | |
Remternetug Details Alzheimer's disease | Phase 3 Data readout | |
Pirtobrutinib Details Blood cancer, Cancer, Lymphoma, Chronic lymphocytic leukemia | Phase 3 Data readout | |
Mirikizumab Details Crohns disease | Phase 3 Data readout | |
Emgality® (galcanezumab-gnlm) Details Migraines | Phase 3 Data readout | |
Abemaciclib Details Castration-resistant prostate cancer | Phase 3 Data readout | |
Tirzepatide Details Obesity | Phase 3 Data readout | |
Lebrikizumab Details Skin disease/disorder, Atopic dermatitis | Phase 3 Update | |
Orforglipron Details Type 1 diabetes | Phase 3 Update | |
Orforglipron Details Obesity | Phase 3 Update | |
Verzenio® (Abemaciclib ) Details Cancer, Breast cancer | Phase 3 Update | |
Retatrutide Details Obesity | Phase 3 Initiation | |
Peresolimab /LY3462817 Details Rheumatoid arthritis, Autoimmune disease | Phase 2 Update | |
Mirikizumab (Pediatric) Details Ulcerative colitis | Phase 2 Update | |
AK-OTOF Details OTOF-mediated hearing loss | Phase 1 Update |